Edition:
United Kingdom

Cellectar Biosciences Inc (CLRB.OQ)

CLRB.OQ on NASDAQ Stock Exchange Capital Market

2.70USD
21 Sep 2018
Change (% chg)

$-0.06 (-2.17%)
Prev Close
$2.76
Open
$2.76
Day's High
$2.79
Day's Low
$2.63
Volume
24,127
Avg. Vol
34,406
52-wk High
$20.40
52-wk Low
$2.03

Latest Key Developments (Source: Significant Developments)

Cellectar Biosciences Provides Update On FDA Import Alert
Monday, 24 Sep 2018 

Sept 24 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR BIOSCIENCES PROVIDES AN UPDATE ON THE FDA IMPORT ALERT.CELLECTAR BIOSCIENCES INC - SINCE NOTIFICATION OF IMPORT ALERT, CO HAS BEEN ASSISTING CPDC TO SECURE TIMELY REMOVAL OF IMPORT ALERT.CELLECTAR BIOSCIENCES - FDA INITIATED DIRECT TALKS WITH CO FOR POSSIBLE EXEMPTION FOR CLR 131 FROM IMPORT ALERT PLACED ON CPDC.  Full Article

Cellectar And Orano Med Announce Collaboration To Develop New Phospholipid Drug Conjugate
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR AND ORANO MED ANNOUNCE COLLABORATION TO DEVELOP NEW PHOSPHOLIPID DRUG CONJUGATE.CELLECTAR BIOSCIENCES INC - CO, ORANO MED INTEND TO EVALUATE NEW PDC IN UP TO THREE ONCOLOGY INDICATIONS.CELLECTAR BIOSCIENCES - COLLABORATION TO FOCUS ON DEVELOPMENT OF NOVEL PDC UTILIZING ORANO MED'S UNIQUE ALPHA EMITTER CONJUGATED TO CO'S PHOSPHOLIPID ETHER.CELLECTAR BIOSCIENCES INC - UNDER TERMS OF AGREEMENT, EARLY PRECLINICAL COSTS WILL BE SHARED EQUALLY BETWEEN ORGANIZATIONS.CELLECTAR BIOSCIENCES INC - BOTH PARTIES HAVE AN OPTION TO ADVANCE AND COMMERCIALIZE PDC ALONE OR IN COLLABORATION WITH EACH OTHER.  Full Article

Cellectar Reports Positive Phase 2 Interim Data For CLR 131 In Relapsed/Refractory DLBCL Patients
Wednesday, 18 Jul 2018 

July 18 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR REPORTS POSITIVE PHASE 2 INTERIM DATA FOR CLR 131 IN RELAPSED/REFRACTORY DLBCL PATIENTS.CELLECTAR BIOSCIENCES - AS A RESULT OF FAVORABLE OUTCOMES, CO HAS EXPANDED COHORT TO INCLUDE UP TO 30 ADDITIONAL PATIENTS.CELLECTAR BIOSCIENCES INC - OBSERVED RESPONSES FROM STUDY TO DATE SHOW OVERALL TUMOR REDUCTION RANGED FROM 60% TO GREATER THAN 90%.CELLECTAR BIOSCIENCES INC - INTERIM DATA FROM STUDY SHOW A 33% OVERALL RESPONSE RATE AND A 50% CLINICAL BENEFIT RESPONSE.  Full Article

Cellectar Announces 1-For-10 Reverse Stock Split
Friday, 13 Jul 2018 

July 13 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR ANNOUNCES 1-FOR-10 REVERSE STOCK SPLIT.CELLECTAR BIOSCIENCES INC - ANNOUNCES A 1-FOR-10 REVERSE SPLIT OF ITS COMMON STOCK, EFFECTIVE AT CLOSE OF BUSINESS TODAY.  Full Article

Cellectar Granted Orphan Drug Designation For CLR 131
Wednesday, 9 May 2018 

May 9 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT RHABDOMYOSARCOMA.  Full Article

Cellectar Biosciences On Jan 3, Notified Affected Employees Of Its Plan To Reduce Its Workforce By 6 Positions
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR BIOSCIENCES - ON JAN 3, NOTIFIED AFFECTED EMPLOYEES OF ITS PLAN TO REDUCE ITS WORKFORCE BY 6 POSITIONS -SEC FILING.CELLECTAR BIOSCIENCES-TO RECORD NON-CASH EXPENSES OF ABOUT $1.2 MILLION IN QUARTER ENDED DEC 31 & CASH COSTS OF ABOUT $0.2 MILLION IN 2018, RELATING TO SHUTDOWN.CELLECTAR BIOSCIENCES - IN JAN 2018, CO BEGAN IMPLEMENTING SHUTDOWN OF ITS MANUFACTURING OPERATIONS AT CO'S HEADQUARTERS IN MADISON, WISCONSIN.  Full Article

Cellectar Announces Expansion of Relapsed/Refractory Multiple Myeloma Cohort In Phase 2 Trial of CLR 131
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Cellectar Biosciences Inc ::CELLECTAR ANNOUNCES EXPANSION OF RELAPSED/REFRACTORY MULTIPLE MYELOMA COHORT IN PHASE 2 TRIAL OF CLR 131.CELLECTAR BIOSCIENCES - WILL INCREASE TARGETED PATIENT ENROLLMENT IN R/R MULTIPLE MYELOMA COHORT OF CO'S CURRENTLY ENROLLING CLR 131 PHASE 2 CLINICAL TRIAL.  Full Article

Cellectar Biosciences posts Q3 loss of $0.26 per share
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences reports third quarter 2017 financial and corporate performance.Q3 loss per share $0.26.Cash and cash equivalents as of September 30, 2017 were about $5.7 million​.  Full Article

Cellectar updates median overall survival from phase 1 trial in advanced multiple myeloma
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Cellectar Biosciences Inc ::Cellectar announces updated median overall survival of 26.2 months from cohort 1 of clr 131 phase 1 trial in advanced multiple myeloma.  Full Article

Cellectar Biosciences gets additional patent for CLR 131, CLR 125 in Japan
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences receives additional Japanese patent for CLR 131 and CLR 125 for the treatment of various solid tumors.Japanese patent office granted it a patent covering both composition of matter and method of use for CLR 131 and CLR 125​.  Full Article

BRIEF-Cellectar Granted Orphan Drug Designation For CLR 131

* CELLECTAR GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT RHABDOMYOSARCOMA Source text for Eikon: Further company coverage: